ReviewFrontiers in neurology2025
Cryptogenic embolic stroke and cancer.
Review in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Histopathological analysis of a retrieved cerebral thrombus revealing occult lung adenocarcinoma: a case report.Journal of medical case reports · 2026Article
- Early risk stratification and temporal biomarker patterns of trousseau syndrome-related cerebral infarction in lung cancer.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oncologic and cerebrovascular diseases are among the diseases with the highest incidence rate and are leading causes of disability and mortality. The relationship between cancer and cerebrovascular disease has been studied for decades, yet it remains a challenge. Stroke, in relation to oncologic diseases, has particularities in its diagnosis and treatment. Cancer is an established risk factor for ischemic stroke. The highest risk of stroke occurs within the first 6 months after a cancer diagnosis and in patients with metastases. Between 2 and 10% of patients initially diagnosed with cryptogenic stroke are subsequently diagnosed with cancer within 1 year. The mechanism underlying cryptogenic ischemic stroke associated with oncologic disease is acquired hypercoagulability, which is the most frequent mechanism underlying stroke in patients with cancer. Sometimes, cancer presents itself as non-bacterial thrombotic endocarditis (NBTE) with cerebral infarction. Strokes are usually more severe, and their clinical presentation can be focal or multifocal. D-dimer levels are significantly elevated in patients with cancer-associated stroke. Magnetic resonance imaging (MRI) usually shows embolic lesions across several arterial territories, including both carotid territories and the vertebrobasilar territory. Patients with cancer-associated stroke face a higher risk of recurrence, recurrent thromboembolism, early neurological deterioration, and mortality. Patients with both stroke and cancer should be considered for thrombolysis (recombinant tissue plasminogen activator (rTPA) or tenecteplase) and endovascular treatment. Low-molecular-weight heparin is usually used empirically when a hypercoagulable state is suspected, and few studies have supported the use of direct oral anticoagulants as an option with similar efficacy. The objective of this review was to synthesize all relevant information available to date on neoplasia as a cause of cryptogenic embolic stroke and to provide useful insights for everyday clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.